Study of Adoptive Immunotherapy in Relapsed and Non-resectable Sarcomas After Multimodal Treatment.

Inclusion Criteria for part 1 * Patients with histologically documented unresectable sarcomas which progressed after first or further line treatments for relapsing disease who could be enrolled in Part 2 of study immediately or after a new line of treatment; * Karnofsky score ≥ 70% (patients with Karnofsky score ≥ 50% are eligible if it depends solely on orthopedic problems) * Estimated life expectancy \> 3 months; * Adequate bone marrow functions: * Signed informed consent; * Negative serum or urine pregnancy test within 48 hours from collection of peripheral blood or from lympho cyto apheresis (if post-pubertal female patients); * Archived histological tumour sample available Inclusion Criteria for part 2 * Patients with histologically documented unresectable sarcomas which progressed after a first or further line treatments for relapsing disease * Measurable disease (bone lesions are included); * Karnofsky score ≥ 70% (patients with Karnofsky score ≥ 50% are eligible if its depend solely on orthopedic problems) * Estimated life expectancy \> 3 months; * Adequate bone marrow, hepatic and renal functionality * Signed informed consent; * Archived histological tumour sample available; * Patients should have a venous central access; * Pregnancy test should be negative 48 hours before treatment for post-pubertal women patients. All post-pubertal patients are to take adequate anti-contraceptive measures during treatment and until 8 weeks after the last dose of treatment. Exclusion Criteria for part 1 * History of Human Immunodeficiency Virus, Hepatitis C Virus, Hepatitis B Virus or Hepatitis A Virus infection; * Patients receiving chemotherapy and/or immunotherapy and/or anti-tumour agents and/or radiotherapy on more than 10% of bone marrow area two weeks before peripheral blood collection or lymphocytapheresis; * Patients with neuro-psychiatric disorders or social or geographic problems that would prohibit the understanding or rendering informed consent and compliance with the requirements of this protocol are excluded. Exclusion Criteria for part 2 * Patients with Ewing/Primitive Neuroectodermal Tumor Sarcoma, Rhabdomyosarcoma as well as other rapidly growing sarcomas are not to be included in the study; * Presence of Central Nervous System metastases and/or meningeal neoplastic involvement; * Patients with seizure disorders; * Severe renal, vascular, cardiac, hepatic, lung disorders; * Patients with any severe and/or uncontrolled medical conditions such as unstable angina pectoris, heart failure ≥ grade 2, a recent heart attack within 6 months, uncontrolled heart non arrhythmia uncontrolled metabolic disorders, cirrhosis, uncontrolled hypertension * Patients with a non-optimal ex-vivo expansion of autologous CIK cells during Part 1 (\< 0.5 x 107/kg CIK cells); * History of Human Immunodeficiency Virus, Hepatitis C Virus, Hepatitis B Virus or Hepatitis A Virus infection; * Presence of bleeding disorders; * Patients undergoing renal dialysis; * Presence of uncontrolled diabetes * Patients unable to swallow oral medications; * Patients receiving concomitant steroid or immunotherapy (except corticosteroids with a daily dosage equivalent to prednisone ≤ 20 mg for adrenal insufficiency). * Anticancer chemotherapy or experimental drugs or immunotherapy or radiotherapy 2 weeks before entering the study; * Anticancer chemotherapy or experimental drugs or immunotherapy or radiotherapy on target lesions 2 weeks before entering the study; * Prior exposure to CIK cells; * Major surgery 4 weeks before entering the study; * Minor surgery 1 week before entering the study; * Patients with allergic reactions or hypersensibility to excipient * Pregnant or breast-feeding patients; * Patients with neuro-psychiatric disorders or social or geographic problems that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol are excluded.